Clinical Trial Update: A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two doses of CHF6001 DPI (tanimilast) as add-on to maintenance triple therapy in chronic obstructive pulmonary disease with chronic b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF6001 DPI (Tanimilast) (tanimilast)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: TERMINATED